Key result
More recent diagnosis linked to ~62% five-year survival in childhood osteosarcoma alongside chemotherapy advances.
Why the study?
Survival from childhood osteosarcoma and its relationship to changes in treatment over time were investigated to understand improvements in outcomes.
Do changes in treatment over time improve survival in children with non-metastatic appendicular osteosarcoma?
Observational (n=184)
Do changes in treatment over time improve survival in children with non-metastatic appendicular osteosarcoma?
Absolute Event Rate: 62% vs 21%
Survival for childhood osteosarcoma significantly improved over the 20th century, mirroring the introduction of effective chemotherapy and multidisciplinary care.
Survival gains in young non-metastatic osteosarcoma patients may reflect treatment evolution; leaves open the dominant drivers for modern protocols.
We have reviewed the data from our regional Bone Tumour Registry on patients with osteosarcoma diagnosed between 1933 and 2004 in order to investigate the relationship between survival and changes in treatment. There were 184 patients with non-metastatic appendicular osteosarcoma diagnosed at the age of 18 or under. Survival was calculated using Kaplan-Meier curves, and multivariate analysis was performed using the Cox regression proportional hazards model. The five-year survival improved from 21% between 1933 and 1959, to 62% between 1990 and 1999. During this time, a multi-disciplinary organisation was gradually developed to manage treatment. The most significant variable affecting outcome was the date of diagnosis, with trends in improved survival mirroring the introduction of increasingly effective chemotherapy. Our experience suggests that the guidelines of the National Institute for Clinical Excellence on the minimum throughput of centres for treatment should be enforced flexibly in those that can demonstrate that their historical and contemporary results are comparable to those published nationally and internationally.
No takes yet. Share an insight, caveat, or question.
Foster et al. (2007) conducted an observational in non-metastatic appendicular osteosarcoma (n=184). Date of diagnosis (1990-1999) vs. Date of diagnosis (1933-1959) was evaluated on Five-year survival. More recent date of diagnosis was associated with improved five-year survival for childhood osteosarcoma, increasing from 21% (1933-1959) to 62% (1990-1999) alongside advances in chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: